Source of List of GLP-1 receptor agonists

{{Infobox list | name = List of GLP-1 receptor agonists | subtitle = Reference material | Scope = Agonists at the GLP-1 receptor, alone or with others | Excluded = DPP-4 inhibitors, which raise endogenous hormone }} This '''list''' enumerates agonists at the [[GLP-1 receptor]], including those that also engage other receptors of the glucagon-secretin family. DPP-4 inhibitors are excluded: they raise endogenous incretin concentrations rather than agonising the receptor directly. See [[Dipeptidyl peptidase-4]].{{r|drucker2018}} Status is given as approved or investigational without specifying jurisdiction, since approval differs between countries. See [[Regulatory status by jurisdiction]].{{r|ada2024}} Compounds appearing here are covered by their own articles where one exists. Inclusion is not an endorsement, and several entries are investigational compounds not approved anywhere.{{r|usp1503}} == GLP-1 receptor agonists == | Compound | Route | Interval | Status | |---|---|---|---| | [[Exenatide]] | Subcutaneous | Twice daily or weekly | Approved | | [[Lixisenatide]] | Subcutaneous | Daily | Approved | | [[Liraglutide]] | Subcutaneous | Daily | Approved | | [[Dulaglutide]] | Subcutaneous | Weekly | Approved | | [[Semaglutide]] | Subcutaneous | Weekly | Approved | | [[Oral semaglutide]] | Oral | Daily | Approved | | [[Orforglipron]] | Oral | Daily | Investigational | The list spans three architectures: exendin-derived peptides, [[Albumin binding half-life extension|acylated]] GLP-1 analogues, an Fc fusion, and a non-peptide small molecule. See [[GLP-1 receptor agonist]] for how each solves the half-life problem.{{r|drucker2018}} == Multi-receptor agonists == | Compound | Receptors | Status | |---|---|---| | [[Tirzepatide]] | GIP, GLP-1 | Approved | | [[Survodutide]] | Glucagon, GLP-1 | Investigational | | [[Efinopegdutide]] | Glucagon, GLP-1 | Investigational | | Mazdutide | Glucagon, GLP-1 | Investigational | | [[Retatrutide]] | GIP, GLP-1, glucagon | Investigational | These are treated at [[Dual incretin agonist]] and [[Triple agonist]]. Their receptor ratios are fixed by chemistry and are not comparable between publications, since reported potencies are assay-dependent.{{r|drucker2018}} == Related compounds == Not agonists at the GLP-1 receptor, but discussed alongside them: * [[Cagrilintide]] — an [[Amylin receptor agonist|amylin analogue]], combined with semaglutide as [[CagriSema]]. * Insulin icodec — a weekly basal insulin; a different mechanism entirely. * DPP-4 inhibitors — raise endogenous incretin rather than agonising the receptor. Compounds sold under any of these names outside licensed supply are research chemicals, not the approved products, and this wiki does not represent them as suitable for human use. See [[Research use only]].{{r|usp1503}} Where a compound has no article on this wiki, its name appears here unlinked.{{r|reports}} == References == {{reflist}} <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> == See also == * [[GLP-1 receptor agonist]] * [[Comparison of GLP-1 receptor agonists]] * [[Dual incretin agonist]] * [[Timeline of incretin therapeutics]] * [[Semaglutide]] {{DEFAULTSORT:List of GLP-1 receptor agonists}} [[Category:Lists]] [[Category:Reference material]] [[Category:GLP-1 receptor agonists]]